258 related articles for article (PubMed ID: 30765470)
1. Durable remissions in
Mouttet B; Vinti L; Ancliff P; Bodmer N; Brethon B; Cario G; Chen-Santel C; Elitzur S; Hazar V; Kunz J; Möricke A; Stein J; Vora A; Yaman Y; Schrappe M; Anak S; Baruche A; Locatelli F; von Stackelberg A; Stanulla M; Bourquin JP
Haematologica; 2019 Jun; 104(6):e244-e247. PubMed ID: 30765470
[No Abstract] [Full Text] [Related]
2. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gore L; Locatelli F; Zugmaier G; Handgretinger R; O'Brien MM; Bader P; Bhojwani D; Schlegel PG; Tuglus CA; von Stackelberg A
Blood Cancer J; 2018 Aug; 8(9):80. PubMed ID: 30190453
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
4. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
Kantarjian H; Jabbour E
Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
[TBL] [Abstract][Full Text] [Related]
5. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Gökbuget N; Zugmaier G; Klinger M; Kufer P; Stelljes M; Viardot A; Horst HA; Neumann S; Brüggemann M; Ottmann OG; Burmeister T; Wessiepe D; Topp MS; Bargou R
Haematologica; 2017 Apr; 102(4):e132-e135. PubMed ID: 28082340
[No Abstract] [Full Text] [Related]
6. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Queudeville M; Schlegel P; Heinz AT; Lenz T; Döring M; Holzer U; Hartmann U; Kreyenberg H; von Stackelberg A; Schrappe M; Zugmaier G; Feuchtinger T; Lang P; Handgretinger R; Ebinger M
Eur J Haematol; 2021 Apr; 106(4):473-483. PubMed ID: 33320384
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
Jen EY; Xu Q; Schetter A; Przepiorka D; Shen YL; Roscoe D; Sridhara R; Deisseroth A; Philip R; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jan; 25(2):473-477. PubMed ID: 30254079
[TBL] [Abstract][Full Text] [Related]
8. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
9. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of blinatumomab: a real world data.
Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
Gestrich CK; Sadri N; Sinno MG; Pateva I; Meyerson HJ
Br J Haematol; 2020 Oct; 191(2):e61-e64. PubMed ID: 32729113
[No Abstract] [Full Text] [Related]
12. Blinatumomab significantly improves overall survival.
Burki TK
Lancet Oncol; 2017 Apr; 18(4):e203. PubMed ID: 28285842
[No Abstract] [Full Text] [Related]
13. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
Dombret H; Topp MS; Schuh AC; Wei AH; Durrant S; Bacon CL; Tran Q; Zimmerman Z; Kantarjian H
Leuk Lymphoma; 2019 Sep; 60(9):2214-2222. PubMed ID: 30947585
[TBL] [Abstract][Full Text] [Related]
14. Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
Mikhailova E; Roumiantseva J; Illarionova O; Lagoyko S; Miakova N; Zerkalenkova E; Zharikova L; Olshanskaya Y; Novichkova G; Maschan M; Henze G; Karachunskiy A; Popov A
Br J Haematol; 2022 Jan; 196(1):e6-e9. PubMed ID: 34346071
[No Abstract] [Full Text] [Related]
15. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
16. Phase 1/2 study of blinatumomab in relapsed paediatric ALL.
Brower V
Lancet Oncol; 2016 Dec; 17(12):e525. PubMed ID: 27839960
[No Abstract] [Full Text] [Related]
17. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H; Stein A; Gökbuget N; Fielding AK; Schuh AC; Ribera JM; Wei A; Dombret H; Foà R; Bassan R; Arslan Ö; Sanz MA; Bergeron J; Demirkan F; Lech-Maranda E; Rambaldi A; Thomas X; Horst HA; Brüggemann M; Klapper W; Wood BL; Fleishman A; Nagorsen D; Holland C; Zimmerman Z; Topp MS
N Engl J Med; 2017 Mar; 376(9):836-847. PubMed ID: 28249141
[TBL] [Abstract][Full Text] [Related]
18. A closer look at blinatumomab.
Mattison RJ
Clin Adv Hematol Oncol; 2018 Jun; 16(6):412-414. PubMed ID: 30067611
[TBL] [Abstract][Full Text] [Related]
19. Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant.
Ueda M; de Lima M; Caimi P; Tomlinson B; Little J; Creger R; Lazarus H; Cooper B
Bone Marrow Transplant; 2016 Sep; 51(9):1253-5. PubMed ID: 27088374
[No Abstract] [Full Text] [Related]
20. [Blinatumomab as a bridge to trasplantation in refractory Philadelphia chromosome negative b-cell acute lymphoblastic leukemia: a case report].
Rodríguez-Ferreras A; Zapico-García I
An Sist Sanit Navar; 2019 Apr; 42(1):75-78. PubMed ID: 30706903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
